{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:56:15Z","timestamp":1775843775081,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.xcrm.2023.101237","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:50:36Z","timestamp":1697554236000},"page":"101237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment"],"prefix":"10.1016","volume":"4","author":[{"given":"Christopher","family":"Lischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101237_bib1","doi-asserted-by":"crossref","first-page":"101214","DOI":"10.1016\/j.xcrm.2023.101214","article-title":"High NEK2 expression in myeloid progenitors suppresses T\u00a0cell immunity in multiple myeloma","volume":"4","author":"Cheng","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2023.101237_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2023.101237_bib3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.101237_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/OP.20.01020","article-title":"PD-1 Blockade in Classic Hodgkin Lymphoma","volume":"17","author":"Ansell","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.xcrm.2023.101237_bib5","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101237_bib6","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1038\/sj.onc.1205711","article-title":"The Nek2 protein kinase: a novel regulator of centrosome structure","volume":"21","author":"Fry","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2023.101237_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101237_bib8","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2023.101237_bib9","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2023.101237_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27020347","article-title":"Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development","volume":"27","author":"Dana","year":"2022","journal-title":"Molecules"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:10:42Z","timestamp":1715047842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123004147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666379123004147"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101237","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101237"}}